SOPHiA GENETICS (NASDAQ:SOPH) reported a strong finish to its fiscal year on Tuesday, pairing double-digit revenue growth with significant margin expansion as the healthcare-tech firm moves closer to its goal of operational profitability.
The Switzerland and U.S.-based leader in data-driven medicine announced fourth-quarter revenue of $21.7 million, a 22% increase year-over-year.
For the full year 2025, revenue reached $77.3 million, up 19% compared to 2024.
The growth reflects the increasing adoption of its SOPHiA DDM™ platform, which global hospitals and laboratories use to analyze complex genomic and clinical data.
A standout metric in the report was the company’s adjusted gross margin, which expanded to 74.2% for 2025.
This high-margin profile highlights the scalability of SOPHiA’s cloud-based software model, even as it continues to invest in expanding its reach within oncology and hereditary disorders.
While the company remains in a growth-focused loss phase, its bottom line showed signs of stabilization.
The IFRS net loss for 2025 was $79 million, and the adjusted EBITDA loss stood at $41.5 million.
Management noted that these figures are in line with its strategic roadmap toward financial independence.
Crucially for investors, SOPHiA GENETICS reaffirmed its 2026 financial guidance.
The company expects revenue between $92 million and $94 million and a narrowed adjusted EBITDA loss of $29 million to $32 million.
The company’s management also provided a specific timeline for its "path to black," projecting adjusted EBITDA breakeven around the end of 2026.
Furthermore, it expects to achieve positive adjusted EBITDA in the second half of 2027, provided the current momentum in platform utilization and new customer acquisitions continues at its present pace.